Prab: CSV import

2025-02-20T01:51:08Z

CSV import

← Older revision		Revision as of 01:51, 20 February 2025
Line 57:		Line 57:
	[[Category:Immunosuppressants]]		[[Category:Immunosuppressants]]
	[[Category:Drugs used in rheumatology]]		[[Category:Drugs used in rheumatology]]
			<gallery>
			File:Upadacitinib.svg\|Upadacitinib
			</gallery>

Prab: CSV import

2025-02-15T10:46:26Z

CSV import

Show changes

Prab at 14:32, 9 February 2025

2025-02-09T14:32:13Z

Show changes

Prab: CSV import

2025-02-09T12:01:45Z

CSV import

Show changes

Prab at 01:12, 20 September 2023

2023-09-20T01:12:17Z

New page

== '''What is Upadacitinib?''' ==

* Upadacitinib ('''RINVOQ''') is a '''[[Janus kinase]] (JAK) inhibitor''' used to treat adults with moderate to severe [[rheumatoid arthritis]].

<youtube>
title='''{{PAGENAME}}'''
movie_url=http://www.youtube.com/v/v=AzmT5t-01dk
embed_source_url=http://www.youtube.com/v/v=AzmT5t-01dk
&rel=1
wrap = yes
width=750
height=600
</youtube>

== '''What are the uses of this medicine?''' ==

* RINVOQ is used to treat adults with moderate to severe [[rheumatoid arthritis]] in whom [[methotrexate]] did not work well or could not be tolerated.

== '''How does this medicine work?''' ==

* Upadacitinib is a '''[[Janus kinase]] (JAK) inhibitor'''.
* JAKs are intracellular enzymes which transmit signals arising from cytokine or growth factor-receptor interactions on the cellular membrane to influence cellular processes of hematopoiesis and immune cell function.
* Within the signaling pathway, JAKs phosphorylate and activate Signal Transducers and Activators of Transcription (STATs) which modulate intracellular activity including gene expression.
* '''Upadacitinib modulates the signaling pathway at the point of JAKs, preventing the phosphorylation and activation of STATs'''.
* In human leukocyte cellular assays, '''upadacitinib inhibited cytokine-induced STAT phosphorylation mediated by JAK1 and JAK1/JAK3 more potently than JAK2/JAK2 mediated STAT phosphorylation'''.
* However, the relevance of inhibition of specific JAK enzymes to therapeutic effectiveness is not currently known.

== '''Who Should Not Use this medicine ?''' ==

* This medicine have no usage limitations.

== '''What drug interactions can this medicine cause?''' ==

* RINVOQ should be used with caution in patients receiving chronic treatment with strong CYP3A4 inhibitors (e.g., [[ketoconazole]]).
* Coadministration of RINVOQ with strong CYP3A4 inducers (e.g., [[rifampin]]) is not recommended.

== '''Is this medicine FDA approved?''' ==

* It was approved for use in the United States in 2019.

== '''How should this medicine be used?''' ==

'''Recommended Dosage '''
* The recommended oral dose of RINVOQ is 15 mg once daily with or without food.
* RINVOQ may be used as monotherapy or in combination with [[methotrexate]] or other nonbiologic DMARDs.
* Avoid initiation or interrupt RINVOQ if absolute lymphocyte count is less than 500 cells/mm3, absolute neutrophil count is less than 1000 cells/mm3, or hemoglobin level is less than 8 g/dL.

'''Administration'''
* Take RINVOQ exactly as your healthcare provider tells you to use it.
* Take RINVOQ 1 time a day with or without food.
* Swallow RINVOQ whole with water at about the same time each day. Do not split or break, crush, or chew the tablets.

== '''What are the dosage forms and brand names of this medicine?''' ==

This medicine is available in fallowing doasage form:
* '''As Extended-release tablets:''' 15 mg

This medicine is available in fallowing brand namesː
*'''RINVOQ'''

=='''What side effects can this medication cause?'''==

The most common side effects of this medicine include:
* upper respiratory tract infections
* nausea
* cough
* [[pyrexia]]

RINVOQ may cause serious side effects, including:
* Serious Infections
* Cancer
* Blood Clots ([[thrombosis]])
* Tears (perforation) in the stomach or intestines
* Changes in certain laboratory test results

==''' What special precautions should I follow?''' ==

* Avoid use of RINVOQ in patients with active, serious infection, including localized infections.
* Consider the risks and benefits of RINVOQ treatment prior to initiating therapy in patients with a known malignancy.
* Consider the risks and benefits prior to treating patients who may be at increased risk of [[thrombosis]]. Promptly evaluate patients with symptoms of thrombosis and treat appropriately.
* Events of gastrointestinal perforation have been reported in clinical studies with RINVOQ. Use with caution in patients who may be at increased risk.
* Laboratory monitoring is recommended due to potential changes in lymphocytes, neutrophils, hemoglobin, liver enzymes and lipids.
* RINVOQ may cause fetal harm based on animal studies. Advise females of reproductive potential of the potential risk to a fetus and to use effective contraception.
* Avoid use of RINVOQ with live vaccines.

== '''What to do in case of emergency/overdose?''' ==

* In case of an overdose, it is recommended that the patient be monitored for signs and symptoms of adverse reactions. Patients who develop adverse reactions should receive appropriate treatment.

== '''Can this medicine be used in pregnancy?''' ==

* The limited human data on use of RINVOQ in pregnant women are not sufficient to evaluate a drug-associated risk for major birth defects or miscarriage.

=='''Can this medicine be used in children?'''==

* The safety and efficacy of RINVOQ in children and adolescents aged 0 to less than 18 years have not yet been established. No data are available.

== '''What are the active and inactive ingredients in this medicine?''' ==

* '''Active ingredient:''' upadacitinib
* '''Inactive ingredients:''' microcrystalline cellulose, hypromellose, mannitol, tartaric acid, colloidal silicon dioxide, magnesium stearate, polyvinyl alcohol, polyethylene glycol, talc, titanium dioxide, ferrosoferric oxide, and iron oxide red.

== '''Who manufactures and distributes this medicine?''' ==

* '''Manufactured by: '''AbbVie Ireland NL B.V., Sligo, Ireland
* '''Marketed by:''' AbbVie Inc., North Chicago, IL 60064
* RINVOQ is a trademark of [[AbbVie Biotechnology Ltd]].

== '''What should I know about storage and disposal of this medication?''' ==
* Store RINVOQ in original container at 36°F to 77°F (2°C to 25°C) to protect it from moisture.
* Keep RINVOQ and all medicines out of the reach of children.

{{Extracellular chemotherapeutic agents}}
{{Cytokine receptor modulators}}
{{Portal bar | Medicine}}

[[Category:AbbVie brands]]
[[Category:Anti-inflammatory agents]]
[[Category:Non-receptor tyrosine kinase inhibitors]]
[[Category:Organofluorides]]
[[Category:Pyrrolidines]]
[[Category:Trifluoromethyl compounds]]
[[Category:Ureas]]
{{coststubd}}

Upadacitinib - Revision history

Prab: CSV import

Prab: CSV import

Prab at 14:32, 9 February 2025

Prab: CSV import

Prab at 01:12, 20 September 2023